- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
2022
27 January: Moderna announced that it has begun phase two trials of a booster dose of its vaccine designed to target the Omicron variant. Around 300 people aged 18 years and above will participate in the trial in two groups: people who received two Moderna doses at least six months ago, and people who received two Moderna doses plus a half dose Moderna booster at least three months ago.
2021
20 December: Moderna announced that its booster shot significantly increases antibodies enough to neutralize activity against the Omicron variant. These results are promising as Omicron spreads throughout the world. The vaccine manufacturer stated that it will "continue to rapidly advance an Omicron-specific booster candidate into clinical testing in case it becomes necessary in the future."
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
